CpG oligodeoxynucleotides are potent enhancers of radio- and chemoresponses of murine tumors.
OBJECTIVE
Synthetic oligodeoxynucleotides (ODNs) containing unmethylated cytosine-guanine (CpG) motifs bind to Toll-like receptor 9 (TLR9) and stimulate both innate and adaptive immune reactions and possess anti-tumor activity. We recently reported that CpG ODN 1826 strongly enhances radioresponse of both immunogenic [Milas L, Mason K, Ariga H, et al. CpG oligodeoxynucleotide enhances tumor response to radiation. Cancer Res 2004;64:5074-7] and non-immunogenic [Mason KA, Ariga H, Neal R, et al. Targeting toll-like receptor-9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Clin Cancer Res 2005;11:361-9] murine tumors. Using two immunogenic murine tumors, a fibrosarcoma (FSa) and a mammary carcinoma (MCa-K), the present study explored whether CpG ODN 1826 also improves the response of murine tumors to the chemotherapeutic agent docetaxel (DOC).


METHODS
CpG ODN 1826 (100 microg) was given sc three times: when leg tumors were 6mm, when they grew to 8mm and again 1 week later. DOC (33 mg/kg iv) and local tumor radiation (10Gy) were given when tumors were 8mm. Effects of the treatments were assayed by tumor growth delay, defined as days for tumors to grow from 8 to 12 mm in diameter.


RESULTS
Treatment with CpG ODN 1826 resulted in strongly enhanced response of FSa tumors to radiation and MCa-K tumors to the chemotherapeutic agent DOC. Enhancement of tumor treatment response was demonstrated by a strong prolongation in the primary tumor treatment endpoint, tumor growth delay. Coincidentally, this treatment also resulted in a higher rate of tumor cure than that observed after tumor radiotherapy or chemotherapy alone. When all three agents were combined the effect was comparable to that of the combination of CpG ODN 1826 with radiation in the case of FSa or of the combination of CpG ODN 1826 with DOC in the case of MCa-K.


CONCLUSIONS
Overall results show that CpG ODN 1826 can markedly improve tumor response to radiation and chemotherapy (DOC), suggesting that CpG ODNs have potential to be beneficial when used singly or in combination with other standard treatment modalities such as taxane chemotherapy, radiotherapy or both.
Mason
Kathryn A
KA
Department of Experimental Radiation Oncology, The University of Texas, Houston, TX 77030-4009, USA. kmason@mdanderson.org <kmason@mdanderson.org>
Neal
Robert
R
Hunter
Nancy
N
Ariga
Hisanori
H
Ang
Kian
K
Milas
Luka
L
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D003131:Combined Modality Therapy; D004247:DNA / Q000008:administration & dosage / Q000494:pharmacology*; D000077143:Docetaxel; D004357:Drug Synergism; D005260:Female; D016246:Lymphocytes, Tumor-Infiltrating / Q000187:drug effects / Q000528:radiation effects; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy / Q000235:genetics / Q000473:pathology / Q000532:radiotherapy; D051379:Mice; D009374:Neoplasms, Experimental / Q000188:drug therapy* / Q000235:genetics / Q000532:radiotherapy*; D009838:Oligodeoxyribonucleotides; D012513:Sarcoma, Experimental / Q000188:drug therapy / Q000235:genetics / Q000473:pathology / Q000532:radiotherapy; D043823:Taxoids / Q000008:administration & dosage / Q000494:pharmacology*
C423449:CpG ODN 1826; D009838:Oligodeoxyribonucleotides; D043823:Taxoids; D000077143:Docetaxel; D004247:DNA